---
layout: default
title: Tretinoin
parent: Model Prediction Only (L5)
nav_order: 799
evidence_level: L5
indication_count: 10
---

# Tretinoin
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Tretinoin: From Acute Promyelocytic Leukemia to Rheumatoid Nodulosis

## One-Sentence Summary

> Tretinoin (all-trans retinoic acid) is a retinoid best known for treating acute promyelocytic leukemia and, in topical form, acne.
> The TxGNN model predicts a possible association with **Rheumatoid Nodulosis**,
> but this direction is currently supported by **0 clinical trials** and **0 publications** — it is a pure knowledge-graph signal with no corroborating evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded in evidence pack (`original_indications` empty); commonly known use is Acute Promyelocytic Leukemia / topical acne |
| Predicted New Indication | Rheumatoid Nodulosis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 |
| Canada Market Status | ✗ Not Marketed |
| Number of DINs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this drug in the evidence pack (`original_moa: [Data Gap]`). Tretinoin is generally known as a RAR/RXR (retinoic acid receptor) agonist, and its efficacy in acute promyelocytic leukemia — via induction of leukemic cell differentiation — is well established in the literature outside this dataset.

For the top-ranked prediction, rheumatoid nodulosis, no known biological pathway connects retinoid receptor signaling to the formation or resolution of rheumatoid nodules. The model's own rationale field states this explicitly: the score reflects only a knowledge-graph association (0.998), with no mechanistic or clinical support, and the absence of original-indication/MOA data makes it impossible to construct a credible mechanistic hypothesis at this time.

It is worth noting that lower-ranked candidates in this dataset show more nuanced (and in one case, contradictory) mechanistic signals — for example, retinoic acid signaling has documented, but directionally inconsistent, effects on osteoarthritis (rank 7). This suggests the overall TxGNN output for this drug reflects graph proximity (e.g., shared pathway or receptor neighborhoods) rather than a validated therapeutic signal for rheumatoid nodulosis specifically.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## Canada Market Information

Tretinoin currently has no marketed Health Canada licenses in this dataset (`total_licenses: 0`, `market_status: Not marketed`). No DIN entries are available to list.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The predicted indication (rheumatoid nodulosis) has no clinical trials, no literature, and no mechanistic support beyond the raw TxGNN graph score — this is an L5, model-only signal (`decision_stage: S0`) and does not meet the bar to advance to safety or clinical evaluation.

**To proceed, the following is needed:**
- TFDA/Health Canada label warnings and contraindications (currently a **Blocking** data gap — DG001)
- Confirmed mechanism of action data for tretinoin (currently a **High**-severity data gap — DG002)
- Original indication documentation, to properly assess similarity between tretinoin's approved use and rheumatoid nodulosis
- Preclinical or mechanistic studies specifically linking retinoid signaling to rheumatoid nodule pathophysiology, before this candidate can be considered for further evaluation

*Note: If the goal is to evaluate tretinoin's most literature-supported repurposing signal in this dataset, rank 7 (osteoarthritis, L4/S1) has actual literature evidence — though the findings are directionally mixed and warrant a separate, dedicated evaluation rather than being treated as supportive of the top-ranked candidate above.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

